Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

SPARC expression in resected pancreatic cancer patients treated with Gemcitabine: results from the CONKO-001 study

Item Type:Article
Title:SPARC expression in resected pancreatic cancer patients treated with Gemcitabine: results from the CONKO-001 study
Creators Name:Sinn, M. and Sinn, B.V. and Striefler, J.K. and Lindner, J.L. and Stieler, J.M. and Lohneis, P. and Bischoff, S. and Blaeker, H. and Pelzer, U. and Neuhaus, P. and Dietel, M. and Doerken, B. and Oettle, H. and Riess, H. and Denkert, C.
Abstract:BACKGROUND: Previous investigations in pancreatic cancer suggested a prognostic role for SPARC (secreted protein acidic and rich in cysteine) expression in the peritumoral stroma but not for cytoplasmic SPARC expression. The aim of this study was to evaluate the impact of SPARC expression in pancreatic cancer patients treated with gemcitabine compared to untreated patients. PATIENTS AND METHODS: CONKO-001 was a prospective randomized phase III study investigating the role of adjuvant gemcitabine as compared to observation. Tissue samples of 160 patients were available for SPARC immunohistochemistry on tissue-microarrays to evaluate its impact on patient outcome. RESULTS: Strong stromal SPARC expression was associated with worse disease-free survival (DFS) and overall survival (OS) in the overall study population (DFS: p= 0.005, OS: p=0.033). Its negative prognostic impact was restricted to patients treated with gemcitabine (DFS: p=0.007, OS: p=0.006). High cytoplasmic SPARC expression also was associated with worse patient outcome (DFS: p=0.041, OS: p=0.011). Again the effect was restricted to patients treated with gemcitabine. In multivariable analysis, SPARC expression was independently predictive of patient outcome. CONCLUSIONS: Our data confirm the prognostic significance of SPARC expression after curatively intended resection. The negative prognostic impact was restricted to patients who received adjuvant treatment with gemcitabine, suggesting SPARC as a predictive marker for response to gemcitabine.
Keywords:Pancreatic Cancer, SPARC, Adjuvant Therapy, Gemcitabine, CONKO-001
Source:Annals of Oncology
ISSN:0923-7534
Publisher:Oxford University Press (U.K.)
Volume:25
Number:5
Page Range:1025-1032
Date:May 2014
Additional Information:Erratum in: Ann Oncol 28(11):2900.
Official Publication:https://doi.org/10.1093/annonc/mdu084
PubMed:View item in PubMed

Repository Staff Only: item control page

Open Access
MDC Library